Fulcrum Therapeutics Inc. (FULC) Prices 6.6M Share Offering at $19/sh

Fulcrum Therapeutics (FULC) PT Raised to $12 at BofA Securities

BofA Securities analyst Tazeen Ahmad raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $12.00 (from $11.00) while maintaining a Underperform rating.... More

UPDATE: Morgan Stanley Upgrades Fulcrum Therapeutics (FULC) to Overweight

(Updated - August 11, 2021 5:49 AM EDT)

Morgan Stanley analyst Matthew Harrison upgraded Fulcrum Therapeutics (NASDAQ: FULC) from Equalweight to Overweight with a price target of $34.00 (from $12.00).

The analyst comments " Despite the ~125% increase in valuation today,FULC still only has an EV of... More

Fulcrum Therapeutics Inc. (FULC) Announces $100M Proposed Public Offering of Common Stock

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All of the shares... More

Fulcrum Therapeutics (FULC) PT Raised to $30 at Credit Suisse

Credit Suisse analyst Judah C. Frommer raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $30.00 (from $20.00) while maintaining a Outperform rating.... More

Fulcrum Therapeutics' (FULC) FTX-6058 Data is Strong Start, Sets Stage for In-Patient Trial in 4Q21 - Analyst

Earlier today, Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced positive interim results from its ongoing single- and multiple-ascending dose (SAD and MAD) Phase 1 trial with FTX-6058 in healthy adult volunteers.

Results from the MAD portion of the trial demonstrated proof of biology as evidenced by a dose proportional induction in HBG mRNA and accompanying increases in HbF-containing reticulocytes... More

Fulcrum Therapeutics Inc. (FULC) Halted on LUDP, Up 114%

Fulcrum Therapeutics Inc. (NASDAQ: FULC) Halted on LUDP, Up 114%

Fulcrum Therapeutics (FULC) PT Raised to $45 at Stifel

Stifel analyst Dae Gon Ha raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $45.00 (from $39.00) while maintaining a Buy rating.

Fulcrum Therapeutics Inc. (FULC) Climbs 48%

Fulcrum Therapeutics Inc. (NASDAQ: FULC) Climbs 48%

Fulcrum Therapeutics Inc. (FULC) Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced positive interim results from the ongoing single- and multiple-ascending dose (SAD and MAD) Phase 1 trial with FTX-6058 in healthy adult volunteers. FTX-6058 is an investigational, potent, and selective small molecule inhibitor of EED designed to... More